Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 358,522 |
|
|||||
| News | - | ||||||
| Day High | 7.28 | Low High |
|||||
| Day Low | 6.67 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Fulcrum Therapeutics Inc | FULC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.31 | -4.39% | 6.75 | 15:10:10 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.00 | 6.67 | 7.28 | 7.06 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,446 | 358,522 | $ 6.91 | $ 2,477,657 | - | 2.43 - 13.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:10:38 | 16 | $ 6.7379 | USD |
Fulcrum Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 416.2M | 61.94M | - | 2.81M | -97.34M | -1.57 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Fulcrum Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FULC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.81 | 7.81 | 6.67 | 7.29 | 445,077 | -1.06 | -13.57% |
| 1 Month | 9.76 | 10.09 | 6.67 | 8.63 | 557,435 | -3.01 | -30.84% |
| 3 Months | 7.04 | 13.70 | 6.67 | 9.58 | 644,485 | -0.29 | -4.12% |
| 6 Months | 3.66 | 13.70 | 3.14 | 7.47 | 620,611 | 3.09 | 84.43% |
| 1 Year | 2.45 | 13.70 | 2.43 | 5.52 | 1,021,764 | 4.30 | 175.51% |
| 3 Years | 11.47 | 33.0975 | 2.25 | 11.42 | 994,818 | -4.72 | -41.15% |
| 5 Years | 14.50 | 33.0975 | 2.25 | 11.44 | 667,857 | -7.75 | -53.45% |
Fulcrum Therapeutics Description
| Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability. |
